Organism: Homo sapiens
Gene: 39518_at
Selected probe(set): 224643_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39518_at (224643_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):-4.920534
Number of Samples:3 / 3

Experimental	echinomycin study 1
	Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:---
Control	deferoxamine study 5
	Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:

Relative Expression (log2-ratio):-4.53771
Number of Samples:2 / 4

Experimental	R547 study 1 (24h)
	Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control	vehicle (DMSO) treated DU145 cell sample
	Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours.

Relative Expression (log2-ratio):3.576499
Number of Samples:2 / 3

Experimental	brefeldin A study 1 (0.5ug/ml; p53HCT116)
	Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated p53HCT116 cell sample
	Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Relative Expression (log2-ratio):3.481203
Number of Samples:3 / 3

Experimental	brefeldin A study 1 (0.5ug/ml; HCT 116)
	Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated HCT 116 cell sample
	Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Relative Expression (log2-ratio):-3.4603863
Number of Samples:3 / 5

Experimental	ovarian tumor study 16
	Human epithelial tumor cell samples from the ovary of patients with papillary serous carcinoma. Samples were derived by laser capture microdissection (LCM).
Control	normal ovarian surface epithelial cell sample
	Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue.

Relative Expression (log2-ratio):3.0581512
Number of Samples:4 / 4

Experimental	B-CLL study 11 (rolipram)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control	rolipram study 4 (normal B-cell; 20uM)
	MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

Relative Expression (log2-ratio):2.782877
Number of Samples:4 / 4

Experimental	B-CLL study 11 (DMSO)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control	vehicle (DMSO) treated normal B-cell sample
	MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

Relative Expression (log2-ratio):-2.4875565
Number of Samples:4 / 4

Experimental	R547 study 1 (6h)
	Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 6 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control	vehicle (DMSO) treated DU145 cell sample
	Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 6 hours.

Relative Expression (log2-ratio):2.3491364
Number of Samples:3 / 3

Experimental	influenza virus study 11 (A/H5N3)
	Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection.
Control	influenza virus study 4 (A/H1N1)
	Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

Relative Expression (log2-ratio):-2.2935839
Number of Samples:3 / 21

Experimental	azathioprine study 7 (250uM)
	HepG2 cells treated with compound: azathioprine (250uM; CAS no.:446-86-6) for 24 hours. Azathioprine is hepatotoxic and may cause cholestasis. HepG2 cells were treated with the IC20 concentration measured after 72 hours. ATC code:
Control	vehicle (DMSO) treated HepG2 sample
	HepG2 cells treated with DMSO (0.5% v/v) as solvent control for 24 hours.